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Blind, Placebo-Controlled Trial
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ABSTRACT
Background: Methylated catechin, one of the active ingredients in green tea, has been reported to ameliorate
allergic reactions. We evaluated the efficacy of ‘Benifuuki’ green tea, which contains O-methylated
epigallocatechin-3-O-[3-O-methyl] gallate (O-methylated EGCG), in alleviating Japanese cedar pollinosis
(JCP).
Methods: The study was a double-blind, randomized, placebo-controlled trial. The subjects with JCP were
randomly assigned to drink 700 ml of ‘Benifuuki’ green tea containing O-methylated EGCG or ‘Yabukita’ green
tea (not containing O-methylated EGCG) as a placebo every day from December 2007 through March 2008,
which includes the pollen season. The primary outcome was the area under the curve (AUC) of symptom
scores during the peak pollen season.
Results: Fifty-one adults with JCP participated in the study. Twenty-six subjects were assigned to ‘Benifuuki’
and 25 to ‘Yabukita’. The AUC of symptom score during the peak pollen season in the ‘Benifuuki’ group was
significantly smaller than in the ‘Yabukita’ group for each of runny nose, itchy eyes, tearing, total nasal symp-
tom score, total ocular symptom score, nasal symptom-medication score and ocular symptom-medication
score. The total QOL-related questionnaire score for one week in the peak pollen season was significantly bet-
ter in the ‘Benifuuki’ group. Increase in the peripheral eosinophil count in response to pollen exposure was sup-
pressed in the ‘Benifuuki’ group. No adverse events were reported in either group.
Conclusions: ‘Benifuuki’ green tea containing a large amount of O-methylated EGCG reduced the symptoms
of JCP and has potential as a complementaryalternative medicine for treating seasonal allergic rhinitis.
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ABBREVIATIONS
O-methylated EGCG, O-methylated epigallocatechin-3-O-[3-O-methyl] gallate; JCP, Japanese cedar pollino-
sis; CAMs, complementary and alternative medicines; QOL, quality of life; VAS, visual analogue scale.
INTRODUCTION
Japanese cedar pollen is released from February
through March in much of Japan and causes Japa-
nese cedar pollinosis (JCP), the most prevalent polli-
nosis in Japan.1 JCP causes not only symptoms of rhi-
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Table　1　Catechin and caffeine contents of the test drinks
Content (mg/100 mL)
Benifuuki Yabukita
O-methylated EGCG 5.83 0
EGCG 14.37 13.21
GCG 22.38 20.73
ECG 4.18 2.79
EGC 8.98 14.15
EC 3.73 4.19
Caffeine 20.99 15.85
Total catechin 89.27 94
O-methylated EGCG, O-methylated epigallocatechin-3-O-[3-O-
methyl] gallate; EGCG, epigallocatechin-3-O-gallate; GCG, gallo-
catechin-3-O-gallate; EGC, epigallocatechin; EC, epicatechin.
Fig.　1　Chemical structure of epigallocatechin-3-O-(3-O-
methyl) gallate.
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noconjunctivitis but also symptoms involving other
organs, such as sore throat, cough, headache and
general fatigue. JCP significantly lowers the quality of
life (QOL) of patients.2 The prevalence of JCP has in-
creased drastically over time,3 and it now affects al-
most one fourth of the population.4-6 It is thus a sig-
nificant burden on the nation. Current pharmacother-
apy, including intranasal corticosteroids, non-
sedating antihistamines and leukotriene receptor an-
tagonists, can alleviate the symptoms,1 but maintain-
ing a good QOL remains difficult.
Green tea (Camellia sinensis (L)) is a traditional
and popular drink in many Asian countries. Green tea
has been reported to provide various health bene-
fits,7-10 and several components have been identified
as active ingredients responsible for those bene-
fits.11,12 Among them, a methylated catechin deriva-
tive, 13 O-methylated epigallocatechin-3-O- [ 3-O-
methyl] gallate (O-methylated EGCG) (Fig. 1), was
found to have anti-allergic properties, inhibiting type I
and type IV hypersensitivity reactions.14-17 ‘Beni-
fuuki’, a cultivar that was originally bred to produce
black tea*, contains large amounts of O-methylated
EGCG when it is processed as green tea, whereas the
most-consumed green tea cultivars in Japan, such as
Yabukita, do not contain it.11 (*Black tea is also made
from leaves of Camellia sinensis, but curing the
leaves involves strong oxidation in order to give a
strong flavor, and O-methylated EGCG is destroyed
in the process.)
To prove the anti-allergic properties of ‘Benifuuki’,
we previously performed a double-blind, placebo-
controlled study employing a small number of sub-
jects with JCP and found that it alleviated the symp-
toms.18 We further found in an open-labeled study
that starting drinking ‘Benifuuki’ regularly about 6
weeks before the start of the pollen dispersal season
was more effective than starting after the season had
already begun.19 Here, we present more comprehen-
sive results from a randomized, double-blind,
placebo-controlled trial of green tea for JCP that en-
rolled a larger number of subjects.
METHODS
SUBJECTS
The subjects were male and female volunteers with
JCP who met the following inclusion criteria: (1) Japa-
nese cedar pollen-specific IgE level class 2 (Im-
mune CAP), (2) a history of JCP for at least 2 seasons
before the study, (3) 20-65 years of age and (4) ability
to accurately maintain a diary. Patients were ex-
cluded if they (a) had concomitant sino-nasal disease
(such as perennial allergic rhinitis, rhinosinusitis, na-
sal polyps, nasal septum deviation) that might con-
found accurate determination of the outcomes of the
trial, (b) were undergoing cedar-pollen-specific im-
munotherapy, (c) had undergone sino-nasal surgery
including laser vaporization, (d) had been adminis-
tered anti-allergy drugs within 2 weeks of start of the
study, (e) were being treated for severe systemic dis-
ease or (f) were pregnant or breastfeeding. All pa-
tients gave written informed consent prior to partici-
pation.
PREPARATION OF TEST DRINKS
A ‘Benifuuki’ tea drink was prepared as described
previously.19 It contained O-methylated EGCG at 5.83
mg100 ml. A ‘Yabukita’ tea drink of very similar
color and taste as ‘Benifuuki’ tea, but containing no
O-methylated EGCG, served as a placebo. Table 1
shows the contents of various catechins and caffeine
in the test drinks.
STUDY DESIGN
This was a single-center, double-blind, randomized,
placebo-controlled, parallel-group trial conducted at
Mie National Hospital (Mie, Japan) from December
2007 through March 2008. The patients were ran-
domized to drink a 350-ml bottle of either ‘Benifuuki’
or the placebo, ‘Yabukita’, green tea twice daily (total
700 mlday) during the study period. That period ran
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Fig.　2　Study design (top panel) and Japanese cedar pollen count in 2008 in Tsu City, 
Mie, Japan (bottom panel).
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from the first week of December, approximately 10
weeks before start of the pollen season, until March
31, by which time pollen dispersal has usually ended.
The dose of the test drink was determined based on
the previous studies; In an initial preliminary study,
daily intake of 34 mg O-methylated EGCG, not 17 mg,
resulted in significant improvement in nasal symp-
toms of patients with perennial allergic rhinitis (pub-
lished in Japansese). Then, in an open-label, single-
dose, randomized, parallel-group study for JCP, we
found that daily intake of 700 ml ‘Benifuuki’ green tea
containing about 40 mg of O-methylated EGCG for
1.5 months prior to the cedar pollen season was effec-
tive in reducing symptom scores for JCP.19
They were allowed to take antihistamines and topi-
cal or systemic corticosteroids as rescue medication
for no more than 2 consecutive days. The subjects re-
corded their nasal and other symptoms in a symptom
diary every day. The QOL score and visual analog
scale (VAS) were determined at visits every 2 weeks
and blood sampling was performed at entry and at
the end of the study (Fig. 2). The study protocol was
approved by the Institutional Review Board of Mie
National Hospital, and the study was conducted in ac-
cordance with the Declaration of Helsinki and Good
Clinical Practice guidelines.
POLLEN COUNT
The dispersed pollen count in Tsu City was deter-
mined by the Department of Otorhinolaryngology-
Head and Neck Surgery, Mie University Graduate
School of Medicine, by the gravity method using a
Durham sampler and expressed as numbercm2.
OUTCOME MEASURES
Participants recorded their nasal symptoms (sneez-
ing, runny nose and nasal congestion), ocular symp-
toms (itchy eyes and tearing), sore throat and inter-
ference with daily life in the diary using a 5-point
scale: nil, 0; mild, 1; moderate, 2; severe, 3; very se-
vere, 4. The volume of tea consumed was also re-
corded in the diary. The medication score (MS) was
rated as follows: antihistamine, 1; topical corticoster-
oids, 2; systemic corticosteroids, 3. The total nasal
symptom score (TNSS) was the sum of sneezing,
runny nose and nasal congestion, the total ocular
symptom score (TOSS) was the sum of itchy eyes
and tearing, and the nasal symptom medication score
(NSMS) and the ocular symptom medication score
(OSMS) were the sum of the MS and TNSS or TOSS,
respectively.
Participants also filled out the Japanese Allergic
Rhinitis QOL Standard Questionnaire No. 1 (JRQLQ
No. 1)20 and rated their nasal symptoms on a visual
analog scale (VAS; a 10-cm scale from 0 points = no
nasal symptoms to 10 points = most severe nasal
symptoms) at each visit.
A complete blood count and blood chemistry tests
were performed for each subject at entry and the end
of the study to detect any adverse effect of the test
drinks.
ENDPOINTS
The primary outcome was the area under the curve
(AUC) of the plot of each symptom score during the
peak pollen season. Secondary outcomes were the
weekly symptoms, the total QOL-related question-
naire score, the VAS of nasal symptoms and the num-
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214 Allergology International Vol 63, No2, 2014 www.jsaweb.jp
Table　2　Demographics of the subjects
‘Benifuuki’ group
(n = 26)
‘Yabukita’ group
(n = 25) Statistics
Gender (n, male/female) 8/18 7/18 n.s.
Age (years) 39.6 ± 10.8 39.6 ± 9.3 n.s.
Duration of Japanese cedar pollinosis from the onset (years) 12.1 ± 7.6 13.2 ± 7.5 n.s.
Japanese cedar pollen-specifi c IgE (ImmunoCAP score) 3.8 ± 0.9 3.7 ± 1.0 n.s.
Total nasal symptom score at entry 2.9 ± 0.9 2.9 ± 0.8 n.s.
Data are expressed as the mean ± SD.
Table　3　The area under the curve (AUC) of each symptom score and VAS during the peak pollen season (Mar. 6-26)
Outcome measure ‘Benifuuki’ group (n = 26) ‘Yabukita’ group (n = 25)
Sneezing 30.8 ± 18.0 32.0 ± 17.6
Runny nose 33.8 ± 20.8* 36.9 ± 19.2
Nasal congestion 22.8 ± 20.8 24.7 ± 17.2
Itchy eyes 30.7 ± 20.9** 37.4 ± 19.5
Tearing 17.7 ± 19.9** 21.4 ± 18.9
Sore throat 21.8 ± 19.8 23.6 ± 19.8
Total Nasal Symptom Score 38.0 ± 19.2** 43.0 ± 18.1
Total Ocular Symptom Score 31.5 ± 20.5** 38.2 ± 19.9
Nasal Symptom Medication Score 41.0 ± 22.1** 44.4 ± 19.3
Ocular Symptom Medication Score 35.2 ± 25.0** 39.8 ± 20.0
Interference with daily life 16.5 ± 17.6** 19.0 ± 14.5
Visual Analog Scale 4.23 ± 2.56 4.46 ± 2.62
Data are expressed as the mean ± SD.
**p < 0.01, *p < 0.05; ‘benifuuki’ group vs. ‘yabukita’ group in Mann-Whitney U test.
ber of eosinophils in the peripheral blood.
STATISTICAL ANALYSIS
The background data of the participants, symptom
scores, total QOL-related questionnaire score, AUC
of the symptom scores and VAS during the peak pol-
len season were compared between the ‘Benifuuki’
and Yabukita’ groups using the Mann-Whitney U test.
RESULTS
Seventy-six subjects were screened, and 51 (15 males
and 36 females, mean age 39.6 years) were eligible
for the study. Twenty six subjects were assigned to
‘Benifuuki’ tea and 25 to ‘Yabukita’ tea. There were
no significant differences in the demographics be-
tween the two groups (Table 2). Adherence to con-
suming the test drink was more than 90% for all par-
ticipants throughout the study period. All participants
completed the protocol.
The pollen season started on February 21, and the
peak period of pollen dispersal continued from March
6 to 26. Figure 2 shows the weekly pollen counts.
Table 3 shows the AUC data for the symptom
scores during the peak pollen season. The AUC val-
ues were significantly smaller in the ‘Benifuuki’
group than in the ‘Yabukita’ group for the following
nasal and ocular symptoms: runny nose (p < 0.05),
itchy eyes (p < 0.01) and tearing (p < 0.01). Similarly,
the AUC data for TNSS, TOSS, NSMS and OSMS
were significantly smaller in the ‘Benifuuki’ group
than in the ‘Yabukita’ group (p < 0.01).
Figure 3A plots the TNSS for every week during
the examination period, including the pollen season.
Overall, the TNSS appears to be lower in the ‘Beni-
fuuki’ group compared with the ‘Yabukita’ group. The
score in the week of March 17 was significantly lower
in the ‘Benifuuki’ group (p < 0.01). Similarly, in Fig-
ure 3B, the TOSS in every week appears to be lower
in the ‘Benifuuki’ group than in the ‘Yabukita’ group.
The scores for three weeks beginning from March 3
were significantly lower in the ‘Benifuuki’ group (p <
0.05 in the first and second weeks, p < 0.01 in the
third week).
As shown in Table 3, the AUC of interference with
daily life was significantly smaller in the ‘Benifuuki’
group than in the ‘Yabukita’ group (p < 0.01). The
weekly total QOL-related questionnaire score for the
week of March 10 was significantly higher in the ‘Be-
nifuuki’ group (data not shown), i.e., the QOL of the
subjects taking ‘Benifuuki’ tea was better than with
‘Yabukita’.
The AUC of the VAS for nasal symptoms in the
Efficacy of Benifuuki Green Tea for Pollinosis
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Fig.　3　Changes in weekly total nasal symptom score (TNSS; A) and ocular 
symptom score (TOSS; B) during the examination period. The TNSS for the 
week of Mar. 17 (**p < 0.01) and the TOSS for each of three consecutive weeks 
beginning from Mar. 3 (*p < 0.05 in the fi rst and second weeks; **p < 0.01 in the 
third week) were signifi cantly lower in the ‘Benifuuki’ group. Open circles show 
the ‘Yabukita’ group, closed circles show the ‘Benifuuki’ group, and triangles 
show the pollen count.
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peak pollen season did not differ significantly be-
tween the ‘Benifuuki’ and ‘Yabukita’ tea groups (Ta-
ble 3). The weekly VAS also did not differ between
the two groups during the examination period.
Table 4 compiles the blood chemistry and hematol-
ogy results before and after drinking the test teas. In
the ‘Yabukita’ group, the number of peripheral
eosinophils was significantly (p < 0.05) increased at
the end of the study. In contrast, the increase in pe-
ripheral eosinophils in the ‘Benifuuki’ group was not
observed.
In the ‘Benifuuki’ group, total protein and total cho-
lesterol were significantly decreased at the end of the
study compared with at the start. In the ‘Yabukita’
group, total protein, total cholesterol, aspartate amino
transferase (AST), alanine transaminase (ALT) and
the red blood cell count were significantly decreased.
However, all the changes in both groups were within
the normal ranges.
No adverse events were reported throughout the
study period, and no significant abnormalities were
found in the physical examinations in either group.
DISCUSSION
In this randomized double-blind, placebo-controlled
trial, we found that drinking ‘Benifuuki’ tea signifi-
cantly reduced the symptoms of Japanese cedar polli-
nosis, improved the QOL and suppressed the in-
crease in peripheral eosinophils that is often seen
during the pollen season.
Tea is consumed globally and in especially large
quantities in Japan and China, where it has been used
not only as a daily beverage but also for medicinal
purposes for thousands of years. Tea falls in the cate-
gory of complementary and alternative medicines
(CAMs). CAMs, which include homeopathy, acu-
puncture, herbal medicines and yoga, are very popu-
lar for alleviation of symptoms of allergic rhinitis and
asthma, but evidence-based recommendations are
lacking.21 The use of CAMs in the United States has
been increasing at a substantial rate and the spending
for CAMs exceeds expenditure for all other physician
Masuda S et al.
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Table　4　Blood chemistry and hematology results before and after drinking the test teas
‘Benifuuki’ group (n = 26) ‘Yabukita’ group (n = 25)
Pre Post Pre Post
Total protein (g/dl) 7.51 ± 0.40 7.36 ± 0.36* 7.45 ± 0.38 7.18 ± 0.48**
Glucose (mg/dl) 109.2 ± 34.2 105.3 ± 35.0 105.5 ± 14.7 106.6 ± 28.8
Triglyceride (mg/dl) 129.6 ± 88.1 118.9 ± 85.3 104.4 ± 57.2 116.9 ± 68.8
Total cholesterol (mg/dl) 203.8 ± 29.3 196.3 ± 31.9* 198.8 ± 35.9 189.8 ± 33.5*
Blood urea nitrogen (mg/dl) 11.73 ± 2.63 12.61 ± 5.27 12.35 ± 2.78 12.95 ± 2.82
Creatinine (mg/dl) 0.62 ± 0.17 0.63 ± 0.17 0.62 ± 0.15 0.63 ± 0.14
Serum iron (μg/ml) 83.3 ± 41.6 85.1 ± 35.7 71.9 ± 35.6 77.6 ± 40.3
Aspartate amino transferase (IU/l) 21.0 ± 9.27 19.8 ± 10.7 18.8 ± 4.27 17.6 ± 4.40*
Alanine transaminase (IU/l) 22.5 ± 22.9 19.2 ± 23.9 15.4 ± 8.65 13.2 ± 6.22*
White blood cells (×1/μl) 6065 ± 1263 5823 ± 1421 6280 ± 1256 5992 ± 1716
Red blood cells (×10000/μl) 456.7 ± 42.0 454.9 ± 39.7 450.9 ± 35.5 442.8 ± 32.7*
Hemoglobin (g/dl) 13.30 ± 1.60 13.2 ± 1.49 13.34 ± 1.73 13.0 ± 1.56
Platelets (×10000/μl) 28.5 ± 6.52 28.3 ± 5.77 27.1 ± 5.56 26.2 ± 5.10
Eosinophils (×1/μl) 3.11 ± 2.21 3.73 ± 2.93 3.80 ± 3.34 5.64 ± 4.28*
*Mann-Whitney U test P < 0.05, comparison between pre- and post-data.
**Mann-Whitney U test P < 0.01, comparison between pre- and post-data.
services.22 Some of the reasons for using CAMs in-
clude distrust of conventional science-based medi-
cine, absence of a satisfactory physician-patient rela-
tionship and the belief that CAMs are safe (devoid of
side effects) productsprocedures.21 Recommenda-
tions for the use of CAMs should be based only on
rigorous proof of efficacy derived from high-quality
studies, because of the considerable cost (to patients
and health care systems) and potential risks (such as
malpractice, incorrect prescription and drug interac-
tions) associated with their use in a non-evidenced-
based approach.22 It is necessary to clarify the effects
and risks in vitro at the molecular level and in vivo at
the clinical level by means of well-designed random-
ized, double-blind, placebo-controlled trials.
Mechanism by which ‘Benifuuki’ green tea amelio-
rated the symptoms of pollinosis in this study may be
attributed to the inhibitory effects of its active ingredi-
ent, O-methylated EGCG, on IgE-mediated mast cell
activation, such as histamine and leukotriene release,
and cytokine production and release.17 O-methylated
EGCG, more potently than the non-methylated form
of EGCG, inhibits multiple protein kinases down-
stream of FcεR I on mast cells.17 EGCG was also re-
ported to inhibit proliferation and differentiation of an
eosinophilic cell line, EOL-1.23 The present finding
that the eosinophilia usually seen in allergen-exposed
patients did not occur in those who took ‘Benifuuki’
can be attributed to the anti-eosinophilic effect of O-
methylated EGCG.
In this study, we found that drinking either ‘Beni-
fuuki’ or ‘Yabukita’ for about four months reduced
the serum total cholesterol level, although the mean
pre- and post-trial levels were within the normal
range. Catechins were reported to reduce serum cho-
lesterol,24,25 and our present results appear to confirm
those earlier findings.
Although the efficacy of ‘Benifuuki’ in this study
was statistically significant, its overall effects were not
potent enough to be a new ‘controller’ for pollinosis.
In addition, the number of the scattered pollen in the
year when the study was performed was relatively
small and the efficacy was not tested in years of mas-
sive scattering of the pollen. We do not suggest that
‘Benifuuki’ is an alternative to guideline-based phar-
macologic treatments, such as antihistamines and
topical corticosteroids, but we suspect that the QOL
of patients with seasonal allergic rhinitis can be im-
proved by choosing a “better” tea for daily consump-
tion, one which reduces the symptoms. Moreover,
regular drinking of ‘Benifuuki’ may decrease the use
of medicines, anxiety regarding possible side effects
of medications, the troublesomeness of visiting a hos-
pital and the economic burden on patients.
In conclusion, we demonstrated that ‘Benifuuki’
green tea reduced the symptoms of Japanese cedar
pollinosis and may be beneficial in control of allergic
rhinitis.
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